Obesity associated with poor response to infliximab

Obesity is associated with reduced response to infliximab for patients with rheumatoid arthritis (RA), French researchers have found.

Their study of 76 patients with RA shows those with increased BMI have a lower decrease of DAS28 and Eular good response after six months of treatment.

The researchers say the results add to similar studies about the relationship between anti-TNF therapies and BMI in RA and